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Optimal humoral responses against foreign T-dependent antigens requires 
crosstalk between B-cells and CD4+ T-cells.  Following the binding of B-cells to 
their cognate antigen, B-cells localise to the B:T border, where they receive T cell 
help. This interaction promotes extensive cell division and the migration of B-
cells to the B cell follicles. Later on, the highly proliferative B cell blasts 
differentiate into germinal centres or antibody secreting plasmablasts (Figure 1).  
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Figure 3: Representative flow cytometric plot showing SWHEL Mir-155
+/+ or SWHEL Mir-155
-/- 
donor cells at days 3.5 and 4.5 post immunisation illustrating the defects observed in 
Mir-155-/- B220+ HEL BCR+ B cell blasts (red), B220+ HEL BCRlo germinal centre B-cells (black) 
or B220lo HEL BCRlo plasmablast B-cells (grey) compared to Mir-155+/+ B-cells (A). The 
number of donor-derived HEL-specific plasmablast B-cells was calculated per 106 
lymphocytes at day 3.5, 4.5 and 6.5 post immunisation in Mir-155+/+ (black) or Mir-155-/- 
(grey) mice (B). N=16-19 independent Mir-155+/+ samples and 10-24 independent Mir-155-/- 
samples. Data is representative of at least two independent experiments. The mean ± SEM 
is shown. An unpaired non-parametric Mann-Whitney T test was used for statistics.  HEL-
specific antibody titres of the indicated immunoglobulins were measured in the serum of 
Mir-155+/+ (black) or Mir-155-/- (grey) donors (C). 
Figure 6: The groups of genes with known functions were discovered by GOrilla analysis 
using the genes that were downregulated (A) and mRNA levels confirmed by qRT-PCR (B) or 
upregulated (C) in SWHEL Mir-155
-/-B-cells compared to SWHEL Mir-155
+/+ B-cells. 
Figure 5: SWHEL HEL BCR
+ B220lo Mir-155+/+ (black) or Mir-155-/- (grey) plasmablast B-cells 
were analysed for activated caspases at the time points shown (A). An unpaired Student’s t-
test was used for statistics. Expression of the human Bcl2 transgene (huBCL2) in SWHEL x 
Mir-155+/+x Bcl2 (black line) or SWHEL x Mir-155
-/- x Bcl2 (solid grey line) plasmablast B-cells, 
compared to negative control (single grey line, B). Representative FACS plot showing the 
gating strategy for analysis of adoptively transferred SWHEL Mir-155
+/+ or Mir-155-/- B-cells 
expressing a human Bcl2 transgene at day 4.5 post immunisation (C). The number of splenic 
SWHEL Mir-155
+/+ or Mir-155-/- B-cells with or without the expression of a human Bcl2 
transgene (D).  The frequency of active caspases in miR-155 sufficient and deficient B-cells 
at day 4.5 post immunisation (E). Data is representative of at least two independent 
experiments. Statistics calculated using One Way ANOVA where *P<0.05, **P<0.01, 
****P<0.001. 
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Figure 4: SWHEL Mir-155
+/+ or Mir-155-/- B-cells were assessed for CFSE dilution, Mir-155+/+ 
(black line), Mir-155-/- (grey line), negative control (filled grey line) (A). EdU incorporation in 
Mir-155+/+ (black bars), Mir-155-/- (grey bars) at the time points indicated. The mean ± SEM 
is shown. Unpaired T test was used for statistics (B). SWHEL Mir-155
+/+ or Mir-155-/- B-cells 
were analysed at 4.5 days post immunisation and analysed for cell cycle by DAPI staining. 
Frequency of G1 or S-G2-M phases in Mir-155+/+ (black bars) or Mir-155-/- (grey bars) SWHEL 
plasmablast B-cells is shown. Unpaired T test was used for statistical calculations. The mean 
± SEM is shown. Data is representative of at least two independent experiments. 
Figure 1: Differentiation of naive B-cells into extrafollicular PBs, GCs or plasma cells 
Introduction 
These rapidly emerging plasmablasts are found in the extrafollicular tissue where 
they continue to expand until they cease proliferation and enter apoptosis [1]. 
The ability of B-cells to quickly differentiate into short-lived antibody secreting 
cells to produce neutralising antibodies of different isotypes can be critical to 
contain the spread of infections [2]. Among the genes that regulate the 
extrafollicular response in a B-cell intrinsic manner is microRNA-155 (miR-155) [3, 
4] . We previously showed that mice lacking miR-155 in B-cells produce a lower 
number of IgM and IgG secreting plasmablasts relative to their wild type 
counterparts [4]. Furthermore, we identified PU1 as a key mir-155 target for this 
process [5]. However, whether the loss of cellularity of miR-155 deficient 
plasmablasts is due to a differentiation block, impaired proliferation or survival 
remains to be understood. 
In order to elucidate the effects of miR-155 on  plasmablast B-cell differentiation, 
SWHEL B-cells (CD45.2
+) sufficient or deficient in miR-155 were injected into B6SJL 
(CD45.1+) mice and then stimulated with HEL antigen coupled to sheep red blood 
cells (HEL-SRBCs, Figure 2). 
Figure 2: Tracking miR-155 deficient B-cells in vivo using the SWHEL system (A). Flow 
cytometry plot showing HEL expression on conjugated HEL-SRBCs (B). 
SWHEL transgenic B-cells either wild type or mir-155-/- bearing a rearranged hen 
egg lysosome (HEL)-specific VDJH element targeted into the IgH chain locus 
combined with an HEL-specific k L-chain transgene were adoptively transferred 
into wild type congenic recipients and immunised with HEL-SRBCs to promote T-
dependent responses. 
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We analysed B-cell differentiation of antigen activated miR-155 sufficient and 
deficient B-cells using flow cytometry by staining for the transgenic HEL BCR and 
B220. 
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miR-155 is essential for the proliferation of 
plasmablast B-cells 
After establishing that miR-155 was critical for the plasmablast B-cell response, we 
next sought to determine the underlying cellular mechanisms. We started by 
monitoring the proliferation of antigen specific B-cells. 
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B-cells lacking miR-155 showed a reduced number of highly dividing cells 
compared to wild type at 2.5 days post immunisation which became more 
pronounced at day 3.5 (Figure  4A). We then measured the amount of cells in S-
phase after incorporation of a pulse of the thymidine analogue EdU by 
plasmablasts at days 4 and 4.5 (Figure 4B). SWHEL Mir155-/-  plasmablast B-cells 
exhibited significantly less S-phase cells, suggesting a cell cycle defect. Supporting 
this observation, we found a significantly increased proportion of Mir-155-/- 
plasmablasts in the G1 phase of the cell cycle and a significantly reduced frequency 
in the S-G2-M phase compared to wildtype B-cells, when DNA was quantified by 
DAPI staining (Figure 4C). 
miR-155 protects plasmablast B-cells from 
apoptosis 
Next, we asked whether miR-155 deficient B-cells were undergoing increased 
apoptosis compared to their wild type counterparts. Flow cytometry  analysis 
showed that Mir155-/- plasmablasts expressed a significantly increased proportion 
of active caspases compared to Mir155+/+ plasmablasts at both 3.5 and 4.5 days 
following activation (Figure 5A). In an attempt to rescue the number of mir-155-/- 
plasmablasts by blocking apoptosis, we crossed the SWHEL Mir155
+/+ or SWHEL 
Mir155-/- mice with human Bcl2 (6) transgenic mice (Figure 5B). The presence of 
the BCL2 transgene increased the frequency and number of plasmablasts (Figure 
5C/D) and reduced the frequency of active caspases (Figure 5E), but the  altered 
phenotype was not fully restored. 
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miR-155 regulates genes  
We next sought to determine the molecular pathways disrupted in Mir155-/- 
plasmablast B-cells by comparing the transcriptome of miR-155 deficient  B-cells 
with their wildtype counterparts. CD45.2+ HEL BCR+ B220lo plasmablast B-cells from 
miR-155-sufficient or -deficient mice were sorted to over 98% purity  and their 
trancriptome analysed by microarray at 4.5 days post immunisation. We defined 
differentially expressed genes as those genes with a fold change of at least 1.3 
between miR-155 deficient and miR-155 sufficient plasmablasts and a corrected p-
value of less than 0.05. We observed 410 upregulated and 652 downregulated 
genes in mir-155 -/- plasmablasts relative to their wild type counterparts. We then 
use the gene ontology enrichment analysis tool GOrilla [7] to look for pathway 
enrichment in the differentially expressed genes. Downregulated and upregulated 
genes were sorted into functional processes and ranked according to their p value  
(Figure 6). 
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• MiR-155 is required to sustain the plasmablast response and is essential 
for plasmablast survival and proliferation. 
• MiR-155 deficient, HEL-specific plasmablast B-cells showed an increase 
in apoptosis and defects in cell cycle progression and DNA replication 
compared to wild type controls.  
• Through transcriptome analysis of miR-155 sufficient and deficient SWHEL 
B cells we determined that miR-155 indirectly regulates genes involved 
in cellular processes such as the DNA metabolic process, DNA 
nucleosome assembly, DNA replication initiation and the mitotic cell 
cycle process which provides new insight into antibody production 
during the early response to infection and vaccination. 
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